Patents by Inventor Aileen Nerio
Aileen Nerio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040029897Abstract: Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.Type: ApplicationFiled: January 13, 2003Publication date: February 12, 2004Applicant: Cerus CorporationInventors: David Cook, John E. Merritt, Aileen Nerio, Henry Rapoport, Adonis Stassinopoulos, Susan Wollowitz
-
Publication number: 20030082510Abstract: Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4′ and 5′ derivatives of psoralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.Type: ApplicationFiled: July 30, 2002Publication date: May 1, 2003Applicant: Cerus CorporationInventors: Susan Wollowitz, Aileen Nerio
-
Patent number: 6514987Abstract: Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.Type: GrantFiled: July 2, 2000Date of Patent: February 4, 2003Assignee: Cerus CorporationInventors: David Cook, John E. Merritt, Aileen Nerio, Henry Rapoport, Adonis Stassinopoulos, Susan Wollowitz, Jan Matejovic, William A. Denny
-
Publication number: 20020182581Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: ApplicationFiled: March 12, 2002Publication date: December 5, 2002Applicant: Cerus CorporationInventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 6455286Abstract: Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4′ and 5′ derivatives of proralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.Type: GrantFiled: February 9, 2000Date of Patent: September 24, 2002Assignee: Cerus CorporationInventors: Susan Wollowitz, Aileen Nerio
-
Patent number: 6410219Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: March 30, 2000Date of Patent: June 25, 2002Assignee: Cerus CorporationInventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 6194139Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: September 28, 1999Date of Patent: February 27, 2001Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 6177441Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results.Type: GrantFiled: January 23, 1998Date of Patent: January 23, 2001Assignee: Cerus CorporationInventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 6171777Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 7, 1995Date of Patent: January 9, 2001Assignee: Cerus CorporationInventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 6143490Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 7, 1995Date of Patent: November 7, 2000Assignee: Cerus CorporationInventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 6133460Abstract: Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8- positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4' and 5' derivatives of psoralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.Type: GrantFiled: November 20, 1998Date of Patent: October 17, 2000Assignee: Cerus CorporationInventors: Susan Wollowitz, Aileen Nerio
-
Patent number: 6093725Abstract: Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.Type: GrantFiled: January 6, 1998Date of Patent: July 25, 2000Assignee: Cerus CorporationInventors: David Cook, John E. Merritt, Aileen Nerio, Henry Rapoport, Adonis Stassinopoulos, Susan Wollowitz, Jan Matejovic
-
Patent number: 6017691Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: February 9, 1996Date of Patent: January 25, 2000Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 6004741Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.Type: GrantFiled: October 23, 1997Date of Patent: December 21, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5871900Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.Type: GrantFiled: November 7, 1997Date of Patent: February 16, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5712085Abstract: Psoralen compounds are synthesized which have substitutions on the 4,4',5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. Also disclosed are compositions comprising 4' or 5'-primary amino substituted psoralens in a synthetic media.Type: GrantFiled: June 5, 1995Date of Patent: January 27, 1998Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5691132Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes. In particular, quinacrine mustard is used to inactivate pathogens in red cell compositions with retention of red cell function.Type: GrantFiled: November 14, 1994Date of Patent: November 25, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, David Cook, Aileen Nerio
-
Patent number: 5625079Abstract: Synthesis of 4,8-dialkyl-4'-bromomethyl-5'-methylpsoralen and 4,8-dialkyl-5'-bromomethyl-4'-methylpsoralen compounds useful as intermediates.Type: GrantFiled: June 5, 1995Date of Patent: April 29, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
-
Patent number: 5593823Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: November 14, 1994Date of Patent: January 14, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
-
Patent number: 5559250Abstract: Novel compounds for photodecontaminating biological material which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 5, 1995Date of Patent: September 24, 1996Assignee: Steritech, Inc.Inventors: David Cook, Susan Wollowitz, Aileen Nerio